Mechanism of action Arristada is injected into the intramuscles as an atypical antipsychotic. In one 12-week clinical trial involving 622 participants, the efficacy of extended<unk>  was demonstrated. Its mechanism of action is not completely known, but is thought to be converted by enzyme-mediated hydrolysis to N-hydroxymethyl<unk> . The hydroxymethyl<unk>  is then hydrolysed to<unk> . Efficacy could be mediated through a combination of partial agonist activity D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. Since it is a newly approved drug by the FDA, many validation of mechanisms of action are still being studied. Pharmacodynamics<unk>  exhibits high affinity for serotonin 5-HT1A, 5-HT2A receptors, dopamine D2, and dopamine D3. Moderate affinity is exhibited for serotonin 5-HT7, alpha1-adrenergic, dopamine D4, histamine H1, and serotonin re-uptake site. No affinity for cholinergic muscarinic receptors have been found. Pharmacokinetics Aristada’s activity in the body is due to<unk>  and also dehydro-aripiprazole. Dehydro-aripirazole has been shown to have affinities for D2 receptors. These D2 receptors have similarities to<unk>  whereas they represent 30-40% of exposure of<unk>  in plasma. Bioactivation of<unk>  (N-lauroyloxymethylaripiprazole) into<unk> , with N-hydroxymethylaripiprazole as an intermediate. After five to six days of the single intramuscular injection appearance of<unk>  in circulation, it additionally will be released for 36 days. In the fourth monthly injection, consecutive doses of Aristada will reach steady-state. With additional supplements of the oral<unk>  at a dosage of 21 days during the first dose of Aristada,<unk>  concentrations within 4 days can reach therapeutic levels.
Aripiprazole lauroxil
Electroconvulsive therapy
Brief psychotherapy
Desmethylclozapine
Serdexmethylphenidate/dexmethylphenidate
Clozapine
Lorpiprazole
Insight-oriented psychotherapy